1. Japan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Immuno-Biological Laboratories Co., Ltd.

Immuno-Biological Laboratories Co., Ltd.

TTSE:4570
1,003.00
JPY
+5.00
(+0.50%)
12.50BMarket Cap
Nov 11Next Earn
Immuno-Biological Laboratories Co., Ltd.
TSE:4570
(Tokyo Stock Exchange)

Recent

price

1,003.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
JPY
171.9
148.51
129.8
105.21
111.35
109.34
101.8
101.01
92.58
65.6
64.72
69.53
85.32
87.69
104.1
107.91
- -
Revenue per Share
-16.79
6.95
24.83
-18
-24.21
-4.86
-287.53
-7.01
-19.83
-76.01
-34.23
-27.78
-31.11
20.05
26.74
35.33
- -
Basic EPS, GAAP
15.23
15.89
32.64
-7.64
-27.51
-108.89
-62.84
9.72
-28.91
-69.25
-22.29
-10.01
2.84
12.36
13.3
28.74
- -
Free Cash Flow per Basic Share
- -
- -
- -
4.71
0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
332.38
339.55
364.58
423.85
400.15
412.71
180.82
242.17
245.98
209.21
174.94
146.92
115.81
135.86
162.6
197.93
- -
Book Value per Share
319.25
329.68
357.99
390.31
370.83
386.37
180.82
242.17
245.98
209.21
174.94
146.92
115.81
135.61
162.41
197.79
- -
Tangible Book Value per Share
6
6
6
6
7
7
7
8
8
9
9
9
9
9
9
9
9
Basic Weighted Avg Shares
1,060
915
800
670
729
718
742
758
781
577
603
648
795
817
970
1,005
- -
Sales/Revenue/Turnover
2.39
14.34
10.99
-4.11
-9.2
5.86
-175.94
-6.43
-22.23
-103.24
-39.98
-18.87
7.19
12.77
21.59
27.99
- -
Operating Margin (%)
117
102
86
101
114
84
340
- -
- -
- -
- -
- -
- -
2
15
19
- -
Depreciation Expense
-104
43
153
-115
-158
-32
-2,094
-53
-167
-668
-319
-259
-290
187
249
329
- -
Net Income, GAAP
- -
5.99
6.15
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-9.77
4.68
19.13
-17.11
-21.74
-4.44
-282.45
-6.94
-21.42
-115.85
-52.9
-39.96
-36.46
22.86
25.69
32.74
- -
Profit Margin (%)
736
834
1,037
1,413
1,593
1,320
2,895
2,696
1,561
1,195
980
902
913
1,004
1,109
1,293
- -
Working Capital
87
55
124
77
283
403
1,848
973
286
20
59
105
99
85
35
19
- -
LT Debt
2,049
2,093
2,247
2,795
2,620
2,786
1,341
2,018
2,146
1,948
1,629
1,368
1,079
1,265
1,514
1,843
- -
Total Equity
- -
1.01
0.34
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
2.04
6.58
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-4.93
2.07
7.05
-4.57
-5.88
-1.18
-101.48
-3.13
-8.04
-32.64
-17.82
-17.26
-23.68
15.93
17.92
19.6
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
ST Debt
167
158
- -
LT Borrowings
22
19
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
9
9
9
Market Capitalization
4,424
12,499
8,969

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
Total Current Assets
1,497
1,570
- -
Cash, Cash Equivalents & STI
955
989
- -
Accounts Receivable, Net
178
179
- -
Inventories
348
380
- -
Total Current Liabilities
270
276
- -
Payables & Accruals
- -
- -
- -
ST Debt
167
158
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.08%
4.31%
21.73%
Free Cash Flow
-22.73%
55.07%
116.16%
Net Income, GAAP
672.78%
-21.16%
32.11%
Sales/Revenue/Turnover
4.22%
11.06%
3.66%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
970
2026
- -
- -
- -
- -
1,005
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
26.74
2026
- -
- -
- -
- -
35.33
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Immuno-Biological Laboratories Co., Ltd. engages in the research, development, manufacturing, and supply of various immunological research reagents and diagnostic products worldwide. Its main products include ELISA assay kits for quantitative measurement of targeted substances; customized antibody production services; research support for diseases such as Alzheimer's, metabolic syndrome, and cancer; LipoSEARCH, a service for lipoprotein profiling using gel-filtration high-performance liquid chromatography; LipoTEST, a diagnostic support tool for animal clinics; and customized biomarker testing for lifestyle-related diseases. Additionally, the company operates a protein production business utilizing transgenic silkworms for manufacturing antibodies, diagnostic reagents, human collagen for cosmetic materials, and proteins for drug development. Founded in 1982, the company is headquartered in Fujioka, Japan. Recent major developments include receiving patent approval from the United States Patent and Trademark Office for an Anti-HIV Antibody and its manufacturing method in collaboration with Kumamoto University and others; gaining insurance coverage approval in Japan for its in vitro diagnostic pharmaceutical product Entamoeba Histolytica Antibody ELISA-IBL, scheduled for market release in November 2025; and completing the acquisition of a 58.3% stake in Skylight Biotech Inc. These steps reflect the company's strategic expansion into new diagnostic product markets and enhanced biotechnology capabilities. Immuno-Biological Laboratories serves primarily the life sciences, diagnostics, and research markets, operating globally with a focus on Japan and expanding its international footprint.